ReviewPharmaceuticals (Basel, Switzerland)2020
2019 FDA TIDES (Peptides and Oligonucleotides) Harvest.
Review in Pharmaceuticals (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 94 citations in OpenAlex.
- Peptide Regulation of Ageing: From Experiment to Practice.Current aging science · 2026Review
- Functionalized Indolizines as Potential Anticancer Agents: Synthetic, Biological and In Silico Investigations.International journal of molecular sciences · 2025Article
- Peptide-Drug Conjugates: A New Hope for Cancer.Journal of peptide science : an official publication of the European Peptide Society · 2025Review
- An Improved P(V) Thio-Oligonucleotide Synthesis Platform.Organic letters · 2025Article
- FDA-approved drugs featuring macrocycles or medium-sized rings.Archiv der Pharmazie · 2025Review
- Porous silicon and silica carriers for delivery of peptide therapeutics.Drug delivery and translational research · 2024Review
- Peptide-Based Therapeutics in Cancer Therapy.Molecular biotechnology · 2024Review
- Peptide-encoding gene transfer to modulate intracellular protein-protein interactions.Molecular therapy. Methods & clinical development · 2024Article
- Review
- Review
- Exploring FDA-Approved Frontiers: Insights into Natural and Engineered Peptide Analogues in the GLP-1, GIP, GHRH, CCK, ACTH, and α-MSH Realms.Biomolecules · 2024Review
- Biocompatible strategies for peptide macrocyclisation.Chemical science · 2024Review
- 2023 FDA TIDES (Peptides and Oligonucleotides) Harvest.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Epimerisation in Peptide Synthesis.Molecules (Basel, Switzerland) · 2023Review
- Characterization of the Cardiac Structure and Function of Conscious D2.B10-International journal of molecular sciences · 2023Article
- Conjugation as a Tool in Therapeutics: Role of Amino Acids/Peptides-Bioactive (Including Heterocycles) Hybrid Molecules in Treating Infectious Diseases.Antibiotics (Basel, Switzerland) · 2023Review
- 2022 FDA TIDES (Peptides and Oligonucleotides) Harvest.Pharmaceuticals (Basel, Switzerland) · 2023Article
- A Review: The Antiviral Activity of Cyclic Peptides.International journal of peptide research and therapeutics · 2023Review
- Strategic Approaches to Improvise Peptide Drugs as Next Generation Therapeutics.International journal of peptide research and therapeutics · 2023Review
- Design of novel anti-quorum sensing peptides targeting LuxO to combatIn silico pharmacology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
2019 has been an excellent year in terms of peptides and oligonucleotides (TIDES) approved by the FDA. Despite the drop in the number of total drugs approved by the FDA in 2019 in comparison with 2018 (48 vs. 59), the total number of TIDES authorized increased (seven vs. three). Year after year, TIDES are increasingly present in therapy, as imaging agents, theragnostic and constituent moieties of other complex drugs, such as antibody drug conjugates. This means a consolidation of these kinds of drugs in the pharmaceutical arena, paving the way in the coming years for the approval of others for diverse medical indications. Here the TIDES approved in 2019 are analyzed in terms of chemical structure, medical target, mode of action, and adverse effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.